Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule

Rudolf Lucas, Roberto Montesano, Michael S. Pepper, Michael Hafner, Erwin Sablon, Yves Dunant, Georges E. Grau, Patrick De Baetselier, Daniela Mnnel, Lucie Fransen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In this study, we characterised the anti-tumour as well as the pro-metastatic activities of TNF mutants deficient in their lectin-like activity.16,19 We report that, despite reduced systemic toxicity as compared to wild-type (wt) mTNF, a (T104A) and a (T104A-E106A-E109A) mTNF mutant (triple mTNF) retained most of their necrotic and tumouristatic activities, as measured in a CFS-1 fibrosarcoma and a B16BL6 melanoma tumour model, respectively. These mutants also conserved their anti-angiogenic activity, as measured in an in vitro endothelial morphogenesis assay.26 In contrast, the pro-metastatic activity of the T104A and the triple mTNF mutants in the CFS-1 fibrosarcoma and the 3LL-R Lewis lung carcinoma tumour model was significantly lower than that of the wt molecule. These results thus indicate that the lectin-like domain of TNF is not implicated in its necrotic, tumouristatic and anti-angiogenic activities, but that it can contribute to the pro-metastatic effect of the cytokine. In conclusion, in view of their reduced systemic toxicity and pro-metastatic capacity, but their retained anti-tumour activities, lectin-deficient TNF mutants might prove to be therapeutically interesting alternatives to wt TNF.

Original languageEnglish (US)
Pages (from-to)543-549
Number of pages7
JournalInternational Journal of Cancer
Volume91
Issue number4
DOIs
StatePublished - Feb 15 2001

Fingerprint

Lectins
Fibrosarcoma
Neoplasms
Lewis Lung Carcinoma
Morphogenesis
Melanoma
Cytokines

Keywords

  • Angiogenesis
  • Lectin
  • Metastasis
  • TNF
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. / Lucas, Rudolf; Montesano, Roberto; Pepper, Michael S.; Hafner, Michael; Sablon, Erwin; Dunant, Yves; Grau, Georges E.; De Baetselier, Patrick; Mnnel, Daniela; Fransen, Lucie.

In: International Journal of Cancer, Vol. 91, No. 4, 15.02.2001, p. 543-549.

Research output: Contribution to journalArticle

Lucas, Rudolf ; Montesano, Roberto ; Pepper, Michael S. ; Hafner, Michael ; Sablon, Erwin ; Dunant, Yves ; Grau, Georges E. ; De Baetselier, Patrick ; Mnnel, Daniela ; Fransen, Lucie. / Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. In: International Journal of Cancer. 2001 ; Vol. 91, No. 4. pp. 543-549.
@article{512f3ed5a07d4b859bf83b1f57572b5d,
title = "Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule",
abstract = "In this study, we characterised the anti-tumour as well as the pro-metastatic activities of TNF mutants deficient in their lectin-like activity.16,19 We report that, despite reduced systemic toxicity as compared to wild-type (wt) mTNF, a (T104A) and a (T104A-E106A-E109A) mTNF mutant (triple mTNF) retained most of their necrotic and tumouristatic activities, as measured in a CFS-1 fibrosarcoma and a B16BL6 melanoma tumour model, respectively. These mutants also conserved their anti-angiogenic activity, as measured in an in vitro endothelial morphogenesis assay.26 In contrast, the pro-metastatic activity of the T104A and the triple mTNF mutants in the CFS-1 fibrosarcoma and the 3LL-R Lewis lung carcinoma tumour model was significantly lower than that of the wt molecule. These results thus indicate that the lectin-like domain of TNF is not implicated in its necrotic, tumouristatic and anti-angiogenic activities, but that it can contribute to the pro-metastatic effect of the cytokine. In conclusion, in view of their reduced systemic toxicity and pro-metastatic capacity, but their retained anti-tumour activities, lectin-deficient TNF mutants might prove to be therapeutically interesting alternatives to wt TNF.",
keywords = "Angiogenesis, Lectin, Metastasis, TNF, Therapy",
author = "Rudolf Lucas and Roberto Montesano and Pepper, {Michael S.} and Michael Hafner and Erwin Sablon and Yves Dunant and Grau, {Georges E.} and {De Baetselier}, Patrick and Daniela Mnnel and Lucie Fransen",
year = "2001",
month = "2",
day = "15",
doi = "10.1002/1097-0215(200002)9999:9999<::AID-IJC1090>3.0.CO;2-Y",
language = "English (US)",
volume = "91",
pages = "543--549",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule

AU - Lucas, Rudolf

AU - Montesano, Roberto

AU - Pepper, Michael S.

AU - Hafner, Michael

AU - Sablon, Erwin

AU - Dunant, Yves

AU - Grau, Georges E.

AU - De Baetselier, Patrick

AU - Mnnel, Daniela

AU - Fransen, Lucie

PY - 2001/2/15

Y1 - 2001/2/15

N2 - In this study, we characterised the anti-tumour as well as the pro-metastatic activities of TNF mutants deficient in their lectin-like activity.16,19 We report that, despite reduced systemic toxicity as compared to wild-type (wt) mTNF, a (T104A) and a (T104A-E106A-E109A) mTNF mutant (triple mTNF) retained most of their necrotic and tumouristatic activities, as measured in a CFS-1 fibrosarcoma and a B16BL6 melanoma tumour model, respectively. These mutants also conserved their anti-angiogenic activity, as measured in an in vitro endothelial morphogenesis assay.26 In contrast, the pro-metastatic activity of the T104A and the triple mTNF mutants in the CFS-1 fibrosarcoma and the 3LL-R Lewis lung carcinoma tumour model was significantly lower than that of the wt molecule. These results thus indicate that the lectin-like domain of TNF is not implicated in its necrotic, tumouristatic and anti-angiogenic activities, but that it can contribute to the pro-metastatic effect of the cytokine. In conclusion, in view of their reduced systemic toxicity and pro-metastatic capacity, but their retained anti-tumour activities, lectin-deficient TNF mutants might prove to be therapeutically interesting alternatives to wt TNF.

AB - In this study, we characterised the anti-tumour as well as the pro-metastatic activities of TNF mutants deficient in their lectin-like activity.16,19 We report that, despite reduced systemic toxicity as compared to wild-type (wt) mTNF, a (T104A) and a (T104A-E106A-E109A) mTNF mutant (triple mTNF) retained most of their necrotic and tumouristatic activities, as measured in a CFS-1 fibrosarcoma and a B16BL6 melanoma tumour model, respectively. These mutants also conserved their anti-angiogenic activity, as measured in an in vitro endothelial morphogenesis assay.26 In contrast, the pro-metastatic activity of the T104A and the triple mTNF mutants in the CFS-1 fibrosarcoma and the 3LL-R Lewis lung carcinoma tumour model was significantly lower than that of the wt molecule. These results thus indicate that the lectin-like domain of TNF is not implicated in its necrotic, tumouristatic and anti-angiogenic activities, but that it can contribute to the pro-metastatic effect of the cytokine. In conclusion, in view of their reduced systemic toxicity and pro-metastatic capacity, but their retained anti-tumour activities, lectin-deficient TNF mutants might prove to be therapeutically interesting alternatives to wt TNF.

KW - Angiogenesis

KW - Lectin

KW - Metastasis

KW - TNF

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0035866033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035866033&partnerID=8YFLogxK

U2 - 10.1002/1097-0215(200002)9999:9999<::AID-IJC1090>3.0.CO;2-Y

DO - 10.1002/1097-0215(200002)9999:9999<::AID-IJC1090>3.0.CO;2-Y

M3 - Article

C2 - 11251979

AN - SCOPUS:0035866033

VL - 91

SP - 543

EP - 549

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -